Innovent wins China approval for Jaypirca across all CLL/SLL treatment lines
AI Summary- Innovent announced NMPA approval of Jaypirca monotherapy for adults with CLL/SLL.
- Pirtobrutinib reduced progression or death risk by 80.1% versus bendamustine plus rituximab.
- The expanded indication covers all treatment lines regardless of prior covalent BTK inhibitor use.